BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO
BridgeBio Pharma sg&a expenses for the twelve months ending December 31, 2024 were $0.289B, a 91.87% increase year-over-year.
- BridgeBio Pharma annual sg&a expenses for 2024 were $0.289B, a 91.87% increase from 2023.
- BridgeBio Pharma annual sg&a expenses for 2023 were $0.151B, a 5.17% increase from 2022.
- BridgeBio Pharma annual sg&a expenses for 2022 were $0.143B, a 25.5% decline from 2021.